Axa’s Axsome Therapeutics AXSM Stock Holding History

Axa’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,100	Closed	-$253K	–	1208
2020 Q4	$253K	Hold	3,100	–	–	﹤0.01%	1154
2020 Q3	$221K	Sell	3,100 -5,100	-62%	-$397K	﹤0.01%	1143
2020 Q2	$675K	Buy	+8,200	New	+$631K	﹤0.01%	1016

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Axa's AXSM Position: Q1 2021 in Review

Axa sold out of Axsome Therapeutics (AXSM) in Q1 2021, closing a stake of 3,100 shares — an estimated $253K sold.

Axa first reported a position in AXSM in Q2 2020 and held it in 3 quarters. The position peaked at $675K in Q2 2020. 184 funds tracked by Wall St. Rank hold AXSM as of Q1 2021.

Axa reported no remaining Axsome Therapeutics position as of Q1 2021 after selling out during the quarter.
Axa sold 3,100 Axsome Therapeutics shares in Q1 2021, an estimated $253K.
Axa first reported a position in Axsome Therapeutics in Q2 2020 and held it in 3 quarters.
Axa's Axsome Therapeutics position peaked at $675K in Q2 2020.
184 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2021.

Based on Axa's 13F filing for Q1 2021, filed 14 May 2021.